Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of CTM012 in advanced solid tumors
CTR20253618Phase 2Active
- Sponsor
- Lepu Chuangyi
- Start
- Sep 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CTM012 in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), neuroendocrine prostate cancer (NEPC), glioblastoma (GBM), Nonhematologic neoplasms, sponsored by Lepu Chuangyi. Started Sep 2025; status: active.
02
Drugs
CTM012
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)neuroendocrine prostate cancer (NEPC)glioblastoma (GBM)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20253618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253618.